Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Triple Negative Breast Neoplasms 3Sezary Syndrome 3Mycosis Fungoides 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Gliosarcoma 1Glioma 1Glioblastoma 1Extensive Stage Lung Small Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

vedolizumab 1LDP-02 1Infliximab 1Immunoglobulin G 1Disulfides 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colitis × Immunoglobulin G × Clear all
NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡